Sustained Remission From Weeks 16 to 52 and Weeks 24 to 52 in Patients Treated With Sarilumab: Post-hoc Analysis of SAPHYR Trial in Patients With Polymyalgia Rheumatica.
- The poster presents post-hoc results from the SAPHYR study on the proportion of patients achieving sustained remission and its components at weeks 16 and 24 up to week 52.A higher proportion of patients in the sarilumab arm vs comparator arm achieved sustained remission and its individual components when assessed from week 16 and week 24 up to week 52. Most patients who achieved sustained remission did so rapidly by week 12 with some additional responses observed between weeks 12 and 24. The actual mean daily GC dose administered during the study was lower in the sarilumab arm vs comparator.
- Poster Source: Data included in this poster were originally presented at the European Alliance of Associations for Rheumatology (EULAR) 2023, May 31-Jun 03, Milan, Italy.
| Display Label | Action |
|---|---|
| RheumNow 2024_Dasgupta et al._SAPHYR SR_ encore Poster_11Jan2024_Final | Download Handout |